Research Outline

The objective of the MCI-iCONM Co-Creation Laboratory is to encourage the development of technology that will give people ways of determining their physical condition at a very early stage, and to help provide those people with appropriate options for their own well-being. With this in mind, Mitsui Chemicals, Inc. (MCI) and iCONM will undertake joint research into nanomedicine-based healthcare modalities* and create business schemes for their social implementation. By leveraging the synergies from combining both organizations’ technical, human and physical resources, the laboratory will pursue initiatives aimed at achieving a resiliently healthy society.

*Modalities: Modes of treatment including low molecular weight drugs, antibody drugs, nucleic acid medicine, cell therapy, gene and cell therapy, and gene therapy